Itepekimab (REGN-3500) is a monoclonal antibody of IL-33. Itepekimab reduces airway inflammation and related tissue damage in previous clinical studies. Itepekimab has potential application in asthma, chronic obstructive pulmonary disease (COPD) and atopic dermatitis (AD)[1][2][3][4].
[1]. Wechsler ME, et al. Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma. N Engl J Med. 2021 Oct 28;385(18):1656-1668.
[2]. Rabe KF, et al. Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial. Lancet Respir Med. 2021 Nov;9(11):1288-1298.
[3]. Kosloski MP, et al. Pharmacokinetics and pharmacodynamics of itepekimab in healt adults and patients with asthma: Phase I first-in-human and first-in-patient trials. Clin Transl Sci. 2022 Feb;15(2):384-395.
[4]. Scott JB, et al. Novel treatments for pediatric atopic dermatitis. Curr Opin Pediatr. 2021 Aug 1;33(4):392-401.